Opens in a new tab
Monday, 16 November 2026
EVIDENCE. INTERPRETED.
Policy & Acquisitions

Mergers & Acquisitions

Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.

Advertisement · Remove ads
970 × 90

Latest in Mergers & Acquisitions

214 stories · every one Fact-Checked
ac-immune_home_image_pioneering-precision-medicineMergers & AcquisitionsAC Immune Expands Tau Program Under Lilly AgreementLausanne-based AC Immune amended its 2018 agreement with Eli Lilly to advance new Tau Morphomer small molecules for Alzheimer’s and other neurodegenerative diseases.8 Apr 2026 · 2 min read
Fact-Checked
2528Mergers & AcquisitionsGilead Bolsters ADC Strategy with Tubulis Acquisition Worth Up to $5BGilead Sciences, Inc. agreed to acquisition of Tubulis GmbH, adding clinical-stage ADCs led by TUB-040 in Phase 1b/2 for ovarian cancer and NSCLC, plus next-generation conjugation platforms, in…7 Apr 2026 · 2 min read
Fact-Checked
Gemini_Generated_Image_5zbgzi5zbgzi5zbgMergers & AcquisitionsNeurocrine to Acquire Soleno, Strengthening Rare Disease Portfolio with VYKAT XRNeurocrine Biosciences has agreed to acquire Soleno Therapeutics for $2.9 billion in cash, adding VYKAT XR, a newly approved therapy for hyperphagia in Prader-Willi syndrome, to strengthen its…6 Apr 2026 · 3 min read
Fact-Checked
Gemini_Generated_Image_fsotrzfsotrzfsotMergers & AcquisitionsDenali Therapeutics Inc. Regains Full Rights to DNL593 After Takeda Pharmaceutical Company Ends CollaborationImage Courtesy: Denali (Brand fetch) Denali Therapeutics Inc. regains full rights to DNL593 after Takeda Pharmaceutical Company ends collaboration; Phase…4 Apr 2026 · 3 min read
Fact-Checked
11962Mergers & AcquisitionsRegeneron Partners with TriNetX to Leverage 300 Million Patient Records for Research and Digital InnovationRegeneron has partnered with TriNetX to integrate large-scale genomic, proteomic, and real-world clinical data, expanding its EHR-linked database and advancing AI-driven drug discovery.4 Apr 2026 · 3 min read
Fact-Checked
102581Mergers & AcquisitionsLupin Completes VISUfarma Acquisition, Expands European Ophthalmology PortfolioLupin finalizes the acquisition of VISUfarma B.V., adding over 60 eye care brands and strengthening its specialty presence across key European markets.3 Apr 2026 · 2 min read
Fact-Checked
48114Mergers & AcquisitionsZai Lab, Amgen Partner to Advance DLL3 Dual-Targeting Strategy in SCLCZai Lab partners with Amgen Inc. to evaluate a DLL3-targeting combination of zoci and IMDELLTRA® in ES-SCLC, aiming to improve systemic and intracranial responses in this aggressive cancer.2 Apr 2026 · 3 min read
Fact-Checked
17652Mergers & AcquisitionsBioVersys Strikes Ansamycin Antibiotic Deal with Hackensack Meridian HealthBioVersys and Hackensack Meridian Health will jointly develop ansamycin candidates to address non-tuberculous mycobacterial infections, leveraging complementary expertise in antimicrobial research.1 Apr 2026 · 3 min read
Fact-Checked
104938Mergers & AcquisitionsAxsome-Takeda Deal Brings Balipodect into Late-Stage CNS DevelopmentAxsome Therapeutics strengthens its CNS pipeline by acquiring balipodect, a novel PDE10A inhibitor from Takeda Pharmaceutical Company, with planned Phase 3 development in Schizophrenia.1 Apr 2026 · 2 min read
Fact-Checked
Gemini_Generated_Image_d10zlkd10zlkd10zMergers & AcquisitionsBiogen’s $5.6B Apellis Deal Boosts Immunology and Rare Disease PortfolioBiogen’s $5.6 billion acquisition of Apellis brings two marketed complement therapies, EMPAVELI and SYFOVRE, boosting near-term revenue while expanding its footprint in immunology, nephrology, ophthalmology, and rare immune-driven…1 Apr 2026 · 3 min read
Fact-Checked
15141Mergers & AcquisitionsGalapagos – Gilead Finalize Ouro-Linked Deal to Advance GamgertamigGalapagos and Gilead have finalized a framework agreement linked to Gilead’s acquisition of Ouro Medicines, bringing gamgertamig into a structured co-development pathway for autoimmune diseases.1 Apr 2026 · 2 min read
Fact-Checked
Gemini_Generated_Image_kpgf3lkpgf3lkpgfMergers & AcquisitionsLilly to Acquire Centessa in $6.3B Deal, Expands Orexin Pipeline for Sleep DisordersLilly moves to acquire Centessa following strong Phase 2 data for cleminorexton, aiming to accelerate development of orexin-based therapies for sleep-wake disorders.31 Mar 2026 · 3 min read
Fact-Checked
Page 17 of 18